3-bromoacetylamino benzoylurea: a cancericidal compound used for inhibition of microtubule assembly in tumor cells; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 398525 |
| CHEMBL ID | 480645 |
| SCHEMBL ID | 4198730 |
| MeSH ID | M0290575 |
| Synonym |
|---|
| nsc-708440 |
| nsc708440 |
| 3-bromoacetamido-benzoylurea |
| NCI60_038405 |
| CHEMBL480645 |
| SCHEMBL4198730 |
| 3-bromoacetylamino benzoylurea |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID408692 | Antiproliferative activity against human CEM cells after 72 hrs by trypan blue assay | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity, and structure-activity relationships. |
| AID367225 | Antiproliferative activity against human CEM cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3 | Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents. |
| AID397876 | Cytotoxicity against human CEM cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | Synthesis and activity evaluation of phenylurea derivatives as potent antitumor agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||